{
    "clinical_study": {
        "@rank": "102364", 
        "arm_group": {
            "arm_group_label": "Chloroquine and Primaquine", 
            "description": "Chloroquine (CQ)10mg/kg for day 1, 2 and 5mg/kg for day 3 Primaquine (PQ)0.25mg/kg/day for 14 days"
        }, 
        "brief_summary": {
            "textblock": "This research is intended to study the efficacy of chloroquine (CQ) and primaquine (PQ) for\n      Plasmodium vivax (P.vivax) infection, and also to study the recurrence rate among patients\n      with P.vivax malaria on standard doses of CQ and PQ. For this study, PQ will be withheld for\n      28 days so as to study the efficacy of CQ alone.\n\n      This study will assess whether CQ is still effective against P.vivax or whether there are\n      resistant P.vivax strains in Bhutan."
        }, 
        "brief_title": "Safety and Efficacy of Chloroquine and Primaquine for Vivax Malaria in Bhutan", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Vivax Malaria", 
        "condition_browse": {
            "mesh_term": [
                "Malaria", 
                "Malaria, Vivax"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study aims to assess the efficacy of Chloroquine alone, withholding Primaquine until\n      day 28. Parasitic clearance and recurrence rates will be recorded. Patients whose blood\n      stage of parasites are not cleared with the standard dose of Chloroquine, or any recurrences\n      before day 28, will be treated with second line treatment (ACT).\n\n      The patients blood level of Chloroquine (drug concentration) at the time of a recrudescent\n      infection will de determined to assess whether that could be due to resistance, or due to\n      low level of Chloroquine.\n\n      Any relapses occurring after day 28 when not receiving Primaquine, or after completion of\n      Primaquine dosage for a total of 14 days (from day 29 to 42), will be treated with repeat\n      doses of the initial treatment. The recurrence rates will be recorded so as to develop the\n      next phase of the study where the two different doses of Primaquine (high dose vs. low dose)\n      will be compared."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  >12 months of age\n\n          -  infection with P.vivax parasitaemia monoinfection\n\n          -  presence of axillary temperature >37.5 degrees or history of fever during the past 24\n             hours\n\n          -  ability to swallow oral medication\n\n          -  ability and willingness to comply with the study protocol for the duration of the\n             study, including 12 months follow up\n\n          -  informed consent from the patient/parent/guardian in the case of children\n\n        Exclusion Criteria:\n\n          -  Presence of general danger signs in children aged under 5 years or signs of severe\n             malaria according to the definitions of WHO\n\n          -  Presence of severe malnutrition (defined as a child whose growth standard is below -3\n             z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm\n             circumference < 110 mm);\n\n          -  History of haemolysis or severe anaemia\n\n          -  Acute anaemia <7 mg/dL\n\n          -  Presence of febrile conditions due to diseases other than malaria (e.g. measles,\n             acute lower respiratory tract infection, severe diarrhoea with dehydration) or other\n             known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic\n             diseases, HIV/AIDS);\n\n          -  Regular medication, which may interfere with antimalarial pharmacokinetics\n\n          -  History of hypersensitivity reactions or contraindications to any of the medicine(s)\n             being tested or used as alternative treatment(s)\n\n          -  a positive pregnancy test or lactating"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "1 Year", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with P.vivax infections will be recruited from 6 sentinel sites and will be\n        recruited for the study after informed consent is received."
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01716260", 
            "org_study_id": "Bhutan_APMEN_CQ PQ_2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Chloroquine and Primaquine", 
                "intervention_name": "Chloroquine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Chloroquine and Primaquine", 
                "intervention_name": "Primaquine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Chloroquine", 
                "Chloroquine diphosphate", 
                "Primaquine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 25, 2013", 
        "location": {
            "contact": {
                "last_name": "Dr Yeshey Dorjey, MD"
            }, 
            "contact_backup": {
                "last_name": "Dr Kinley Penjor, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Gelephu", 
                    "country": "Bhutan"
                }, 
                "name": "Vector Diseases Control Program"
            }, 
            "investigator": [
                {
                    "last_name": "Dr Yeshey Dorjey", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Dr Kinley Penjor", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Dr Tashi Peldon", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mr Tobgay Tobgay", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Dr Lorenz von Seidlein", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Bhutan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Parasitic Clearance and Recurrence Rates Among Patients With Vivax Malaria on Chloroquine and Primaquine Therapy", 
        "other_outcome": [
            {
                "measure": "To assess the feasibility of a 12 month follow-up of patients with vivax malaria in Bhutan.", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "To assess the safety of the currently prescribed CQ and PQ regimens in Bhutan.", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "overall_contact": {
            "last_name": "Dr Lorenz von Seidlein, MD", 
            "phone": "+61 8 8922 6998"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Australia: Human Research Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The purpose is to study the efficacy of Chloroquine alone by recording recrudescent rates and parasitic clearance in P.vivax patients who are given a standard dose of Chloroquine treatment.", 
            "measure": "Chloroquine efficacy for P.vivax infections in Bhutan.", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01716260"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "In this study, Primaquine will be administered on day 28, and any relapse will be recorded to study relapse rates over a 12 month period.", 
            "measure": "To study the efficacy of Primaquine.", 
            "safety_issue": "Yes", 
            "time_frame": "Patients with recurrence after day 28 will be recorded."
        }, 
        "source": "Menzies School of Health Research", 
        "sponsors": {
            "collaborator": {
                "agency": "Ministry of Health, Bhutan", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Menzies School of Health Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}